Italy (IT)

Prediction of risk for bleeding, myocardial infarction and mortality after percutaneous coronary intervention in patients with acute coronary syndromes (2022) Ndrepepa G, Neumann FJ, Menichelli M, Richardt G, Cassese S, Xhepa E, Kufner S, et al. Journal article Role of Reticulated Platelets in Cardiovascular Disease (2022) Bongiovanni D, Han J, Klug M, Kirmes K, Viggiani G, Von Scheidt M, Schreiner N, et al. Journal article, Review article Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors (2022) Poch CM, Foo KS, De Angelis MT, Jennbacken K, Santamaria G, Baehr A, Wang QD, et al. Journal article 10-YEAR CLINICAL EVENTS AVOIDED IN DIABETIC AND CHRONIC KIDNEY DISEASE HYPERTENSION PATIENTS TREATED WITH RADIOFREQUENCY RENAL DENERVATION: PROJECTIONS BASED ON 3-YEAR DATA FROM THE GLOBAL SYMPLICITY REGISTRY (2022) Schmieder R, Cao K, Esler M, Kandzari D, Lobo M, Sharp A, Mancia G, et al. Conference contribution Dynamical scaling of correlations generated by short- and long-range dissipation (2022) Seetharam K, Lerose A, Fazio R, Marino J Journal article An Analysis of the Use Pattern of Hyperthermia (HT) in Combination with Radio(chemo)therapy or Chemotherapy in European HT Centers (2022) Ademaj A, Veltsista DP, Marder D, Haelg RA, Puric E, Brunner TB, Crezee H, et al. Conference contribution Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) (2022) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution Ultrasound-detected inflammation is more common in clinically manifest hand osteoarthritis than in painless bony enlarged finger joints: subanalysis of the population-based Bruneck study (2022) Gasperi N, Schreiber N, Bosch P, Adinolfi A, Kleyer A, Hagen M, Gasperi C, et al. Journal article Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) (2022) Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, Fasching P, Iwata H Conference contribution The eROSITA Final Equatorial Depth Survey (eFEDS): X-ray catalogue (2022) Brunner H, Liu T, Lamer G, Georgakakis A, Merloni A, Brusa M, Bulbul E, et al. Journal article